These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 9670678)

  • 1. [The clinical use of Amoxiclav in patients with suppurative meningoencephalitis].
    Kononenko VV; Matiash VI; Vasilenko LG; Okruzhnov NV; Sidorova ZhP
    Lik Sprava; 1998; (2):118-21. PubMed ID: 9670678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibilities to the compounds.
    Gracia M; Ponte C; Soriano F
    Int J Antimicrob Agents; 2005 Apr; 25(4):352-3. PubMed ID: 15784320
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comparative efficacy and safety of amoxiclav (amoxicillin clavulanate) and ampicillin in the treatment of acute bacterial sinusitis].
    Kriukov AI; Sedinkin AA
    Vestn Otorinolaringol; 2004; (1):49-50. PubMed ID: 15029125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R; Alou L; Giménez MJ; Sevillano D; Gómez-Lus ML; Aguilar L; Prieto J
    Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of co-amoxiclav acid against clinical isolates of Escherichia coli.
    Bertrand X; Talon D
    J Antimicrob Chemother; 2001 May; 47(5):725-6. PubMed ID: 11328800
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Laguna B; Echeverría O; Carcas A; Lubomirov R; Casal J; Prieto J
    J Antimicrob Chemother; 2005 May; 55(5):742-7. PubMed ID: 15761068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What pharmacodynamic elements affect Augmentin in man?].
    Jehl F
    Presse Med; 1998 Sep; 27 Suppl 4():20-1. PubMed ID: 9798482
    [No Abstract]   [Full Text] [Related]  

  • 10. Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of co-amoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation.
    Prieto J; Giménez MJ; Balcabao IP; Gómez-Lus ML; Aguilar L
    J Chemother; 1999 Oct; 11(5):345-8. PubMed ID: 10632379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
    Cazzola M; Vinciguerra A; Beghi GF; Paizis G; Giura R; Madonini V; Fiorentini F; Consigli GF; Tonna M; Casalini A
    J Chemother; 1995 Oct; 7(5):432-41. PubMed ID: 8596127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents.
    Koeth LM; Good CE; Appelbaum PC; Goldstein EJ; Rodloff AC; Claros M; Dubreuil LJ
    J Antimicrob Chemother; 2004 Jun; 53(6):1039-44. PubMed ID: 15128729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
    Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
    Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The etiology of purulent meningoencephalitis in pediatrics. The therapeutic implications].
    Games-Eternod J; Solórzano-Santos F; López del Prado J; Alvarez-Hernández L; Ramírez-Cruz F
    Gac Med Mex; 1991; 127(4):315-20. PubMed ID: 1790836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin.
    Alou L; Cafini F; Sevillano D; Unzueta I; Prieto J
    Int J Antimicrob Agents; 2004 May; 23(5):513-6. PubMed ID: 15120734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Co-amoxiclav antibiotic therapy of acute otitis media, exacerbation of otitis media chronica and sinusitis in children].
    Bogomil'skiĭ MR; Minasian VS
    Vestn Otorinolaringol; 1999; (4):22-4. PubMed ID: 10453230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics/pharmacodynamics of the 1000/62.5 formulation of amoxicillin/clavulanic acid in odontostomatology].
    Isla A; Canut A; Rodríguez Gascón A; Pedraz JL
    Enferm Infecc Microbiol Clin; 2005; 23(6):387. PubMed ID: 15970176
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute meningoencephalitis due to Brucella: case report and review of neurobrucellosis in children.
    Türel O; Sanli K; Hatipoğlu N; Aydoğmuş C; Hatipoğlu H; Siraneci R
    Turk J Pediatr; 2010; 52(4):426-9. PubMed ID: 21043393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and diagnostic aspects of relapsing meningoencephalitis due to Brucella suis.
    Wallach JC; Baldi PC; Fossati CA
    Eur J Clin Microbiol Infect Dis; 2002 Oct; 21(10):760-2. PubMed ID: 12415479
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of co-amoxiclav on polymorphonuclear granulocytes from chronic hemodialysis patients.
    Cuffini AM; Tullio V; Giacchino F; Mandras N; Scalas D; Belardi P; Merlino C; Carlone NA
    Am J Kidney Dis; 2001 Jun; 37(6):1253-9. PubMed ID: 11382696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.